Neoadjuvant HER2+ Articles

Exciting Advances Continue in HER2+ Breast Cancer and Other Subtypes
Kurt W. Tauer, MD, FACP, discusses encouraging updates across the spectrum of breast cancer subtypes.
Research Efforts in HER2+ Breast Cancer Focused on Optimizing Novel Agents
Gregory Vidal, MD, PhD, discussed the ways in which currently available and investigational agents are being evaluated in the curative and metastatic settings of HER2-positive breast cancer.
Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy.
Pivotal Data in HER2+ Breast Cancer Transform Paradigm
Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.
Margetuximab Elicits Modest Survival Extension in HER2+ Breast Cancer
The combination of margetuximab and chemotherapy induced a 1.8-month median overall survival increase in patients with pretreated HER2-positive metastatic breast cancer compared with trastuzumab (Herceptin) and chemotherapy.
Tucatinib Triplet Improves Survival in Advanced HER2+ Breast Cancer
Tucatinib combined with trastuzumab and capecitabine improved overall survival and progression-free survival compared with trastuzumab/capecitabine alone in heavily pretreated patients with locally advanced unresectable or metastatic HER2-positive breast cancer.
FDA Grants Trastuzumab Deruxtecan Priority Review for HER2+ Breast Cancer
The FDA has granted a priority review designation to a biologics license application for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer.
Safety Analysis Supports Adjuvant T-DM1 Use in Early HER2+ Breast Cancer
Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.
Lead KATE2 Author Suggests Atezolizumab Benefits HER2+ Breast Cancer Subgroup
Leisha A. Emens, MD, PhD, discusses the rationale behind the KATE2 study and the results that may signal clinical significance.
Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer
As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.
Publication Bottom Border
Border Publication